Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and KAPIL BHALLA.
HAGOP M KANTARJIAN
Connection Strength
2.290
KAPIL BHALLA
  1. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 03; 38(3):545-556.
    View in: PubMed
    Score: 0.235
  2. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348.
    View in: PubMed
    Score: 0.224
  3. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
    View in: PubMed
    Score: 0.212
  4. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.109
  5. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5.
    View in: PubMed
    Score: 0.095
  6. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15; 110(10):3540-6.
    View in: PubMed
    Score: 0.076
  7. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35.
    View in: PubMed
    Score: 0.071
  8. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51.
    View in: PubMed
    Score: 0.070
  9. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
    View in: PubMed
    Score: 0.062
  10. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv. 2024 May 24.
    View in: PubMed
    Score: 0.061
  11. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790.
    View in: PubMed
    Score: 0.058
  12. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342.
    View in: PubMed
    Score: 0.058
  13. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.
    View in: PubMed
    Score: 0.056
  14. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 12; 97(12):1599-1606.
    View in: PubMed
    Score: 0.054
  15. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 12; 97(12):1560-1567.
    View in: PubMed
    Score: 0.054
  16. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
    View in: PubMed
    Score: 0.053
  17. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
    View in: PubMed
    Score: 0.049
  18. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.
    View in: PubMed
    Score: 0.049
  19. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.
    View in: PubMed
    Score: 0.048
  20. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
    View in: PubMed
    Score: 0.048
  21. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.
    View in: PubMed
    Score: 0.048
  22. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
    View in: PubMed
    Score: 0.047
  23. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315.
    View in: PubMed
    Score: 0.047
  24. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229.
    View in: PubMed
    Score: 0.044
  25. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
    View in: PubMed
    Score: 0.041
  26. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.041
  27. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.040
  28. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
    View in: PubMed
    Score: 0.039
  29. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8).
    View in: PubMed
    Score: 0.038
  30. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
    View in: PubMed
    Score: 0.038
  31. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
    View in: PubMed
    Score: 0.037
  32. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.
    View in: PubMed
    Score: 0.036
  33. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43.
    View in: PubMed
    Score: 0.019
  34. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9.
    View in: PubMed
    Score: 0.019
  35. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia. 2006 Nov; 20(11):1989-91.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.